From: Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Approach | Phase | Status | Clinical trial identifier |
---|---|---|---|
Guadecitabine + ipilimumab for unresectable disease | I | Recruiting | NCT02608437 |
Oral azacitidine + pembrolizumab for metastatic melanoma | II | Recruiting soon | NCT02816021 |
Azacitidine + rInterferon alfa2b for stage III/IV unresectable | I/II | Completed, results not reported | NCT00217542 |
Oral azacitidine bioequivalence study | I | Recruiting | NCT02223052 |
Decitabine + vemurafenib + cobimetinib for resistant disease | I/II | Recruiting | NCT01876641 |